Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer
The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa ResultsRamat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF),
Can-Fite found in lab tests that their medicine namodenoson works better when combined with a common cancer drug for pancreatic cancer. This gives them more reason to believe their ongoing patient study might work well, which is what researchers look for before moving forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.